Sustained Benefit Over Time: Interpreting 52-Week Efficacy From MINT

Achieving sustained symptom control remains a central goal in the management of generalized myasthenia gravis, particularly as clinicians seek therapies that not only improve outcomes but maintain those benefits over time. With newer biologic agents targeting upstream immunologic pathways, evaluating durability and consistency of response has become increasingly important for guiding treatment decisions.

At the 2026 AAN Annual Meeting in Chicago, Richard Nowak, MD, MS, associate professor of neurology at Yale School of Medicine, spoke with NeurologyLive® about updated 52-week findings from the phase 3 MINT trial evaluating inebilizumab in patients with generalized myasthenia gravis. Building on the primary 26-week analysis, these longer-term data provide additional context around the trajectory of clinical response and how treatment effects evolve over time, particularly in AChR-positive patients.

In this episode, Nowak breaks down key efficacy outcomes at 52 weeks, including changes in MG-ADL and QMG scores, responder analyses, and trends in treatment separation over time. He also discusses how clinicians should interpret durability of response in the context of steroid tapering and what these findings suggest about long-term disease modification.

At the 2026 AAN Annual Meeting in Chicago, Richard Nowak, MD, MS, associate professor of neurology at Yale School of Medicine, spoke with NeurologyLive® about the phase 3 MINT trial evaluating inebilizumab in patients with generalized myasthenia gravis. The study design incorporated patients with active disease across both AChR- and MuSK-positive populations, while also integrating real-world elements such as concomitant immunosuppressive therapy and a protocol-defined steroid taper. Nowak emphasized how these design features help contextualize both early and longer-term findings.

In this episode, Nowak walks through the structure of the MINT trial, including eligibility criteria, randomization, and dosing, while highlighting the importance of the forced prednisone taper and the rationale behind the 52-week randomized control period, particularly in assessing durability of response in AChR-positive patients.